NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 20 04:00PM ET
73.77
Dollar change
-0.24
Percentage change
-0.32
%
Index- P/E21.88 EPS (ttm)3.37 Insider Own0.00% Shs Outstand3.37B Perf Week-8.98%
Market Cap248.32B Forward P/E15.70 EPS next Y4.70 Insider Trans- Shs Float3.37B Perf Month8.17%
Enterprise Value259.49B PEG1.17 EPS next Q0.91 Inst Own9.71% Short Float1.00% Perf Quarter-6.37%
Income15.05B P/S5.70 EPS this Y26.64% Inst Trans-3.84% Short Ratio3.36 Perf Half Y-31.73%
Sales43.59B P/B16.33 EPS next Y17.37% ROA26.37% Short Interest33.67M Perf YTD-14.24%
Book/sh4.52 P/C41.28 EPS next 5Y18.68% ROE87.53% 52W Range57.00 - 148.15 Perf Year-47.45%
Cash/sh1.79 P/FCF17.38 EPS past 3/5Y25.78% 21.74% ROIC44.25% 52W High-50.21% Perf 3Y39.02%
Dividend Est.1.96 (2.66%) EV/EBITDA11.51 Sales past 3/5Y23.46% 18.15% Gross Margin84.33% 52W Low29.42% Perf 5Y125.67%
Dividend TTM1.66 (2.25%) EV/Sales5.95 EPS Y/Y TTM16.36% Oper. Margin45.11% Volatility1.84% 2.51% Perf 10Y156.90%
Dividend Ex-DateMar 31, 2025 Quick Ratio0.56 Sales Y/Y TTM22.74% Profit Margin34.52% RSI (14)52.28 Recom2.03
Dividend Gr. 3/5Y28.20% 21.81% Current Ratio0.74 EPS Q/Q10.76% SMA200.22% Beta0.66 Target Price98.42
Payout35.93% Debt/Eq0.86 Sales Q/Q15.81% SMA508.07% Rel Volume0.82 Prev Close74.01
Employees76302 LT Debt/Eq0.70 EarningsMay 07 BMO SMA200-19.32% Avg Volume10.02M Price73.77
IPOApr 30, 1981 Option/ShortYes / Yes EPS/Sales Surpr.8.78% 1.73% Trades Volume8,199,073 Change-0.32%
Date Action Analyst Rating Change Price Target Change
Apr-17-25Downgrade BMO Capital Markets Outperform → Market Perform $64
Mar-13-25Upgrade Kepler Hold → Buy
Mar-03-25Downgrade Stifel Buy → Hold
Feb-12-25Initiated Morgan Stanley Equal-Weight
Jan-06-25Upgrade Bernstein Underperform → Mkt Perform
May-30-24Initiated Goldman Buy $156
Apr-12-24Initiated BMO Capital Markets Outperform $163
Jan-23-24Initiated Morgan Stanley Overweight $120
Jan-16-24Resumed UBS Neutral
Dec-01-23Initiated Cantor Fitzgerald Overweight $120
Today 09:02AM
09:00AM
Jun-20-25 07:38PM
07:34PM
12:49PM
10:41AM Loading…
10:41AM
09:40AM
09:31AM
09:30AM
09:28AM
08:04AM
Jun-19-25 10:23AM
Jun-18-25 11:45AM
10:52AM
10:22AM
09:50AM Loading…
09:50AM
09:00AM
08:08AM
07:51AM
07:45AM
Jun-17-25 05:16PM
01:48PM
05:05AM
Jun-16-25 06:21PM
12:35PM
12:31PM
07:04AM
04:24AM
Jun-15-25 05:47AM
05:23AM
04:40AM Loading…
Jun-14-25 04:40AM
Jun-13-25 12:58PM
10:41AM
09:08AM
08:05AM
07:47AM
07:39AM
05:07AM
04:48AM
Jun-12-25 06:02PM
05:45PM
01:22PM
01:06PM
07:55AM
07:00AM
01:45AM
Jun-11-25 10:40AM
10:00AM
09:38AM
09:32AM
09:17AM
08:58AM
03:13AM
Jun-10-25 08:51PM
04:28PM
04:27PM
03:35PM
01:36PM
11:10AM
11:08AM
09:38AM
08:27AM
08:27AM
08:12AM
08:00AM
06:14AM
03:33AM
Jun-09-25 06:49PM
04:08PM
11:47AM
10:18AM
09:43AM
08:11AM
04:00AM
Jun-07-25 08:44AM
Jun-06-25 04:16PM
04:06PM
02:17PM
12:38PM
09:48AM
09:39AM
09:00AM
07:26AM
04:40AM
Jun-05-25 08:45AM
04:15AM
02:00AM
Jun-03-25 08:17AM
Jun-02-25 11:45AM
07:12AM
May-30-25 07:19PM
05:28PM
08:00AM
07:00AM
05:00AM
May-29-25 02:09PM
10:27AM
09:31AM
May-28-25 09:00PM
11:27AM
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novo Nordisk A/S10% OwnerMay 30 '25Proposed Sale2.14921,8971,972,859May 30 08:31 AM